CLVS News and Press, Clovis Oncology Inc. From 07/22/22

The European Medicines Agency (EMA) announced on Friday Rubraca (rucaparib camsylate), a cancer medication marketed by the U.S. biotech Clovis Oncology ( NASDAQ: CLVS ) should no longer be used as a third line treatment for certain cancers due to concerns over safety/quality. ...

First paragraph, second sentence of release should read: Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook in greater detail. (instead of Clovis’ senior management will host a co...

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis’ senior manag...

Clovis Oncology (NASDAQ: CLVS) had a fine Tuesday, with its share price rising by almost 5% to beat the performance of many other biotech stocks, not to mention the S&P 500 index. A new deal announced by a partner of the company that will, hopefully, advance a top Clovis pip...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clovis Oncology (NASDAQ: CLVS ) stock is rallying 7% in mid-morning trading after the company announced  a major deal with NorthStar Medical Radioisotopes . According to the agreement, which was announced by No...

NorthStar Medical said it had signed a long term supply agreement with Clovis Oncology ( CLVS ) for the therapeutic medical radioisotope, actinium-225 ((AC-225)). Clovis plans to use NorthStar's Ac-225 to radiolabel its lead therapeutic candidate currently in development,...

Shares of commercial-stage biotech Clovis Oncology (NASDAQ: CLVS) fell by a noteworthy 14.9% through the first four days of trading this week, according to data provided by S&P Global Market Intelligence . This move lower stands out for two reasons: Why is Clovis' stock ...

Clovis Oncology has recently been on a winning streak of clinical data and corporate updates. As a result, the share price has rocketed off its 52-week lows. The company's theranostic FAP was able to show some efficacy in its Phase I trial. This validated the company's efforts to deve...

Biotech stocks are back in favor as some risk-on activity permeates the broader market. Clovis Oncology (CLVS) shares spiked from under 50 cents to above $3 recently as news about its key drugs stirs up bullish fervor. The stock is at a key resistance level - is a breakout on the ...

Cancer-focused biotech Clovis Oncology ( CLVS ) recorded the second biggest intraday gain for the year on heavy volume on Friday after the company’s shareholders voted against a proposal to implement a reverse stock split. More than 98.8M Clovis ( CLVS ) shares chan...